 SAN DIEGO, July 28, 2021 PRNewswire -- Heron Therapeutics, Inc. Nasdaq: HRTX, a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the results from the HOPE Hernia-1 study of ZYNRELEF bupivacaine and meloxicam in hernia repair surgery have been published online by Pain and Therapy in an article entitled, Opioid-Free Recovery After Hernia Repair With HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting. In this study, ZYNRELEF, used with scheduled over-the-counter oral analgesics acetaminophen and ibuprofen and a personalized opioid prescription algorithm in a real-world environment, enabled more than 90 of patients to be discharged without an opioid prescription, with no callbacks for pain management and 95 of patients to recover opioid-free. 